J&J Bets on Targeted Cell-Death Approach in $3.05B Halda Buyout

Johnson & Johnson (J&J) has agreed to acquire Halda Therapeutics for $3.05 billion, securing Halda's Riptac cell-death platform and its lead candidate HLD-0915. HLD-0915 is an oral small-molecule therapy targeting metastatic castration-resistant prostate cancer (mCRPC), along with other RIPTAC-based programs for solid tumors.